Short Term Outlook For BioPharmX Corporation (NYSE:BPMX)

66

BioPharmX Corporation (NYSE:BPMX) closed its last session at $0.16. The stock traded within a range of $0.140 and $0.170. The company operates in the Healthcare sector with a market capitalization of 19410. Trading volume for BioPharmX Corporation was 8.85 Million in its previous trading session. Currently, BioPharmX Corporation (NYSE:BPMX) has an average volume of 7.12 Million.

Company Profile

BioPharmX Corporation is a specialty pharmaceutical company. The company focuses on the development of novel drug delivery products for women’s health, dermatology and otolaryngology markets. The Company’s product pipeline includes products in categories consists of prescription products, over-the-counter products and dietary supplements. Prescription products in development include molecular iodine pill for the treatment of breast pain associated with fibrocystic breast disease. OTC product pipeline includes a series of medicated bandages, nasal sprays and other products. Supplement product pipeline includes BioPharmX’s breast health pill. Its product candidates include BPX03 a molecular iodine tablet for the treatment of benign breast pain associated with FBC and cyclic mastalgia and BPX01 a non-lipophilic topical antibiotic for the treatment of acne. BioPharmX Corporation is headquartered in Menlo Park, California.

Analyst Views

BioPharmX Corporation (NYSE:BPMX) received a Buy rating from 1 analysts. 0 analysts gave its stock an Outperform rating. 0 analysts say it’s a Hold while 0 analysts provided their expert opinion as Sell.

BioPharmX Corporation (NYSE:BPMX) touched its 1-Year High price of $0.900 on 04/28/17 and its 1-Year Low price of $0.100 on 12/21/17.

EPS & Financials

BioPharmX Corporation (NYSE:BPMX) reported its EPS in the last quarter as $-0.05/Share lagging the analyst estimate of $-0.05/Share by a difference of $0. This showed a surprise of 0% in the last quarter earnings.

For the current quarter, 2 analysts are projecting a mean EPS of $-0.04/share. According to their observations and findings, the stock could provide a high EPS of $-0.03/share and a low EPS of $-0.04/share.

Technical Analysis

By taking a look at the stock’s current statistics it can gauged that the stock candle is BEARISH with HIGH volatility. BioPharmX Corporation (NYSE:BPMX) has a 20-Day average volume of 13.23 Million. According to today’s trading volume BioPharmX Corporation is BELOW its 20-Day Avg. volume with the stock showing ABOVE Abnormal volume in the past 150 days.

Moving average convergence divergence (MACD) shows that the stock is on a PRICE RELATIVITY trend. The trend for the past 10-days shows that the company was in BEARISH territory while an analysis of the last 40-Day trend shows a BULLISH signal. The 100-Day trend also shows a BEARISH trend as well.

The company currently has an insider ownership of 0.7 Percent and Institutional ownership of 32.5 Percent. The return on assets stands at -326.9%, Return on Equity currently is 0% and the Return on Investment value is 0%.

BioPharmX Corporation (NYSE:BPMX) gross margin percentage stands at 0% while its operating margin for the past trailing twelve month is 0 percent and its overall profit margin (ttm) is 0 Percent. The stock is currently moving above its 20-Day Simple Moving Average of 3.67% with a 50-Day Simple Moving Average of 21.91 percent. As of today, the company has a SMA200 (200-day simple moving average) of -47.99 Percent. The Stock has YTD (year to date) performance of 42.92 percent.

The TTM operating margin for the company stands at 0%. The return on invested capital is at 0%, which is good, compared to its peers. The Free Cash Flow or FCF margin is 0.

The company’s stock is currently moving with a -ve distance from the 200 day SMA of approximately -47.99%, and has a solid year to date (YTD) performance of 42.92% which means that the stock is constantly adding to its value from the previous fiscal year end price.